We are testing a new drug, IMGN151, in women with recurrent gynecological cancers to assess its safety and determine the best dose. This study aims to understand how well the drug works and its effects on patients.
We are studying whether adding ARIKAYCE to standard treatment helps people with Mycobacterium xenopi lung infections clear the infection more effectively. The trial will measure how quickly and effectively the treatment works compared to standard care alone.
We are studying whether teriparatide can improve bone metabolism in patients with chronic kidney disease and adynamic bone disorder. This trial compares the effects of treatment to no treatment at all.
We are testing a new bispecific T-cell receptor treatment for patients with solid tumors. The study looks at its effects alone and with a checkpoint inhibitor to see how well it works.
We are studying an artificial cornea model for patients with severe corneal ulcers that don't respond to regular treatments. The goal is to see if it helps heal the ulcers and improves vision.
We are investigating if treatment choices based on biomarker signatures can improve survival and quality of life for patients with metastatic prostate cancer. This study compares these personalized approaches to standard care.
We are comparing two antibiotics to see which one works better for patients with a specific bacterial infection. The study looks at treatment outcomes, relapse rates, and side effects.
We are investigating how well previous participants of a hepatitis B treatment maintain their health over time. This study focuses on those who have stopped certain therapies and aims to understand their long-term outcomes.
We are studying a new drug, Etentamig, combined with standard cancer therapies for adults with relapsed or refractory multiple myeloma. The goal is to assess its safety and impact on disease activity.
We are investigating how ziltivekimab may improve heart health in people who have had a heart attack compared to a placebo. This study aims to see if it can reduce serious heart-related issues.
We are comparing the effects of continuing versus stopping immunosuppression in patients with late renal graft failure. This study aims to see how these approaches impact health outcomes over two years.
We are investigating a new treatment for Chronic Obstructive Pulmonary Disease in both healthy individuals and those with the condition. This study aims to understand how the treatment may work in different populations.
We are studying whether adding contact X-ray brachytherapy to standard treatment can help preserve the rectum and improve survival in patients with intermediate substage rectal adenocarcinoma. We will also assess its impact on quality of life and side effects.
We are comparing standard alectinib dosing to a personalized dosing method based on blood levels for patients with specific alectinib concentrations. The goal is to see if personalized dosing improves treatment outcomes and safety.
We are investigating whether fecal microbiota transfer can help liver cancer patients who are resistant to standard treatments. The study aims to improve immune response and overall survival.
We are investigating a new drug for patients with metastatic HR+/HER2- breast cancer and other advanced solid tumors. The study aims to evaluate its safety and early signs of effectiveness, both alone and with other treatments.
We are studying a combination of two medications for patients with stage III unresectable non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this combination improves survival and disease control compared to standard treatment.
We are studying a new treatment combination for adults with previously untreated follicular lymphoma. The goal is to see if it works better and has fewer side effects than standard chemotherapy.
We are studying whether Corifollitropin alfa can help increase the number of eggs collected from oocyte donors compared to standard daily treatments. This trial involves women using hormone suppression to improve egg quality.
We are testing a new tissue-engineered substitute for patients with cleft palate to see if it is safe and effective for healing and improving quality of life. The study will compare outcomes with standard treatments.